GV steps up to back Tillman Gerngross’ new antibody play against Covid-19 — and he’s already thinking about the IPO

Tillman Gerngross had two good reasons to celebrate on Monday.

First, he felt that Pfizer’s upbeat assessment of its pivotal Covid-19 vaccine data marked …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GV steps up to back Till­man Gern­gross’ new an­ti­body play against Covid-19 — and he’s al­ready think­ing about the IPO